Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. [Source]

Origin: nytimes.com

Category: Clinical Trials

Topics: cancer, breast, metastatic, people, trial, months, survival, median, prolonged, approved, Perjeta, Lives, Patients’, Extend, Greatly, Appears, Cancer, Breast, Roche

Source: http://rss.nytimes.com/c/34625/f/640350/s/3ee6bdec/sc/14/l/0L0Snytimes0N0C20A140C0A90C290Cbusiness0Croche0Ebreast0Ecancer0Edrug0Eappears0Eto0Egreatly0Eextend0Epatients0Elives0Bhtml0Dpartner0Frss0Gemc0Frss/story01.htm